KPTA to call for more investment-oriented government policies in R&D

Published: 2002-06-04 07:00:00

Updated: 2002-06-04 07:00:00

In its meeting of Board of Directors on May 29, the Korean Pharmaceutical Manufacturers Association (KPMA) has recently criticized the government's drug-related policies to arbitrarily lower the insurance drug prices for better finance stability in the national health insurance sector and instead...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK